Literature DB >> 8830833

Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients.

F Fu1, Y Li, S Qian, L Lu, F Chambers, T E Starzl, J J Fung, A W Thomson.   

Abstract

We have shown previously that granulocyte-macrophage colony-stimulating factor-stimulated mouse bone marrow-derived MHC class II+ dendritic cell (DC) progenitors that are deficient in cell surface expression of the costimulatory molecules B7-1 (CD80) and B7-2 (CD86) can induce alloantigen-specific T-cell anergy in vitro. To test the in vivo relevance of these findings, 2 x 10(6) B10 (H2b) mouse bone marrow-derived DC progenitors (NLDC 145+, MHC class II+, B7-1dim, B7-2-/dim) that induced T-cell hyporesponsiveness in vitro were injected systemically into normal C3H (H2k) recipients. Seven days later, the mice received heterotopic heart transplants from B10 donors. No immunosuppressive treatment was given. Median graft survival time was prolonged significantly from 9.5 to 22 days. Median graft survival time was also increased, although to a lesser extent (16.5 days), in mice that received third-party (BALB/c; H2d) DC progenitors. Ex vivo analysis of host T-cell responses to donor and third-party alloantigens 7 days after the injection of DC progenitors (the time of heart transplant) revealed minimal anti-donor mixed leukocyte reaction and cytotoxic T lymphocyte reactivity. These responses were reduced substantially compared with those of spleen cells from animals pretreated with "mature" granulocyte-macrophage colony-stimulating factor + interleukin-4-stimulated DC (MHC class IIbright, B7-1+, B7-2bright), many of which rejected their heart grafts in an accelerated fashion. Among the injected donor MHC class II+ DC progenitors that migrated to recipient secondary lymphoid tissue were cells that appeared to have up-regulated cell surface B7-1 and B7-2 molecule expression. This observation may explain, at least in part, the temporary or unstable nature of the hyporesponsiveness induced by the DC progenitors in nonimmunosuppressed recipients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830833      PMCID: PMC3154742          DOI: 10.1097/00007890-199609150-00021

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  43 in total

1.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo.

Authors:  L A Turka; P S Linsley; H Lin; W Brady; J M Leiden; R Q Wei; M L Gibson; X G Zheng; S Myrdal; D Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

2.  Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice.

Authors:  G J Freeman; F Borriello; R J Hodes; H Reiser; K S Hathcock; G Laszlo; A J McKnight; J Kim; L Du; D B Lombard
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

Review 3.  The role of the CD28 receptor during T cell responses to antigen.

Authors:  P S Linsley; J A Ledbetter
Journal:  Annu Rev Immunol       Date:  1993       Impact factor: 28.527

Review 4.  Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance.

Authors:  T E Starzl; A J Demetris; M Trucco; N Murase; C Ricordi; S Ildstad; H Ramos; S Todo; A Tzakis; J J Fung
Journal:  Hepatology       Date:  1993-06       Impact factor: 17.425

5.  Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation.

Authors:  C D Gimmi; G J Freeman; J G Gribben; G Gray; L M Nadler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

6.  B70 antigen is a second ligand for CTLA-4 and CD28.

Authors:  M Azuma; D Ito; H Yagita; K Okumura; J H Phillips; L L Lanier; C Somoza
Journal:  Nature       Date:  1993-11-04       Impact factor: 49.962

7.  Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation.

Authors:  G J Freeman; J G Gribben; V A Boussiotis; J W Ng; V A Restivo; L A Lombard; G S Gray; L M Nadler
Journal:  Science       Date:  1993-11-05       Impact factor: 47.728

8.  Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.

Authors:  K Inaba; M Inaba; N Romani; H Aya; M Deguchi; S Ikehara; S Muramatsu; R M Steinman
Journal:  J Exp Med       Date:  1992-12-01       Impact factor: 14.307

9.  Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.

Authors:  H Lin; S F Bolling; P S Linsley; R Q Wei; D Gordon; C B Thompson; L A Turka
Journal:  J Exp Med       Date:  1993-11-01       Impact factor: 14.307

10.  Phagocytosis of antigens by Langerhans cells in vitro.

Authors:  C Reis e Sousa; P D Stahl; J M Austyn
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

View more
  84 in total

1.  Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.

Authors:  V Bronte; D B Chappell; E Apolloni; A Cabrelle; M Wang; P Hwu; N P Restifo
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 2.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

Review 3.  Dendritic cells, T cell tolerance and therapy of adverse immune reactions.

Authors:  P A Morel; M Feili-Hariri; P T Coates; A W Thomson
Journal:  Clin Exp Immunol       Date:  2003-07       Impact factor: 4.330

Review 4.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

5.  Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation.

Authors:  Sherrie J Divito; Zhiliang Wang; William J Shufesky; Quan Liu; Olga A Tkacheva; Angela Montecalvo; Geza Erdos; Adriana T Larregina; Adrian E Morelli
Journal:  Blood       Date:  2010-06-24       Impact factor: 22.113

Review 6.  Advancing islet transplantation: from engraftment to the immune response.

Authors:  R F Gibly; J G Graham; X Luo; W L Lowe; B J Hering; L D Shea
Journal:  Diabetologia       Date:  2011-08-10       Impact factor: 10.122

Review 7.  Regulatory dendritic cells for human organ transplantation.

Authors:  Angus W Thomson; Diana M Metes; Mohamed B Ezzelarab; Dalia Raïch-Regué
Journal:  Transplant Rev (Orlando)       Date:  2019-05-13       Impact factor: 3.943

8.  Prolongation of cardiac allograft survival by systemic administration of immature recipient dendritic cells deficient in NF-kappaB activity.

Authors:  Mao-Meng Tiao; Lina Lu; Ran Tao; Lianfu Wang; John J Fung; Shiguang Qian
Journal:  Ann Surg       Date:  2005-03       Impact factor: 12.969

9.  Ex vivo expanded dendritic cells home to T-cell zones of lymphoid organs and survive in vivo after allogeneic bone marrow transplantation.

Authors:  Christoph H Schimmelpfennig; Stephan Schulz; Caroline Arber; Jeanette Baker; Ingo Tarner; Jacqueline McBride; Christopher H Contag; Robert S Negrin
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

Review 10.  The innate immune system in allograft rejection and tolerance.

Authors:  David F LaRosa; Adeeb H Rahman; Laurence A Turka
Journal:  J Immunol       Date:  2007-06-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.